Acute heart failure or acute exacerbation of chronic heart failure
Conditions
Interventions
Experimental group:Intravenous infusion of levosimendan
Sponsors
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Selection criteria (those who meet all of the following criteria can be selected for this clinical study) (1) Meets the diagnostic criteria for acute heart failure in the ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: dyspnea/wheezing and/or NT proBNP or BNP elevation (the diagnostic threshold for AHF is BNP>400 pg/mL; NT proBNP should refer to age factors, below 50 years>450 pg/mL, 50-75 years>900 pg/mL, and above 75 years>1800 pg/mL); (2) Age = 18 years old, regardless of gender; (3) Those who have signed the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria (those who fall under one of the following circumstances cannot be included in this clinical study) (1) Patients with non cardiogenic asthma caused by other reasons; (2) Patients with comorbidities related to mental disorders, which affect the description of symptoms; (3) The researchers believe that it is not suitable for patients to participate in this study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Changes in heart failure grading after treatment (NYHA);;Patient satisfaction with the improvement time and efficacy of heart failure symptoms after treatment/Scale (Likert).; | — |
Primary
| Measure | Time frame |
|---|---|
| Changes in NT proBNP or BNP levels and relief time of wheezing symptoms in patients with acute or chronic heart failure before and after treatment; | — |
Countries
China
Contacts
Public ContactFan Kailiang
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Outcome results
None listed